<DOC>
	<DOCNO>NCT00545454</DOCNO>
	<brief_summary>The primary objective study assess reduction systemic inflammation measure serum level C-reactive protein ( CRP ) . The secondary objective : - ass reduction systemic inflammation measure change acute phase protein , serum amyloid A ( SAA ) cytokine interleukin-6 ( IL-6 ) , clinical American College Rheumatology response rate , morning stiffness duration ; - ass effect pain relief within first 14 day ; - obtain evidence safety tolerability SSR150106 ; - document trough plasma level SSR150106 first metabolite .</brief_summary>
	<brief_title>Activity Safety Oral Administration SSR150106XB Reduction Inflammation Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Either treatmentna√Øve patient , discontinue Rheumatoid Arthritisdirected medication due intolerability insufficient efficacy At least 9 68 tender joint ; 6 66 swollen joint ; morning stiffness 45 min CReactive Protein &gt; =1.8 mg/dl confirm screening period Nonpoor Cytochrome P2D6 metabolizer status Functional Rheumatoid Arthritis class IV Fever Infections hepatitis B , C , HIV Presence history ( &lt; 5 year ) cancer Manifest latent tuberculosis Functional abnormality ( include laboratory value ) judge clinically relevant The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>anti-cytokine</keyword>
	<keyword>anti-chemokine</keyword>
</DOC>